Mumbai: Drugmaker Ranbaxy Laboratories said on Tuesday its unit has launched a generic version of Pfizer’s blood pressure- and cholesterol-lowering drug Caduet in the United States (US) following an agreement between the two companies.
Caduet pills make their way through the manufacturing process at one of Pfizer’s manufacturing facilities. Photo: Bloomberg
Caduet has annual sales of $339 million in the US, Ranbaxy said in a statement.
The terms of the agreement were not disclosed.
Ranbaxy, majority-owned by Japan’s Daiichi Sankyo, last week launched a generic version of Lipitor, the world’s top selling drug, which is also a Pfizer brand.